Related Experiment Video
Updated: Mar 12, 2026
Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
Published on: August 23, 2016
Inhibition of STAT Pathway Impairs Anti-Hepatitis C Virus Effect of Interferon Alpha
Lan-Juan Zhao1, Sheng-Fei He, Yuan Liu
1Department of Microbiology, Shanghai Key Laboratory of Medical Biodefence, Second Military Medical University, Shanghai, China.
Background/Aims:
Signal transducer and activator of transcription (STAT) pathway plays an important role in antiviral efficacy of interferon alpha (IFN-α). IFN-α is the main therapeutic against hepatitis C virus (HCV) infection. We explored effects of IFN-α on HCV replication and antiviral gene expression by targeting STAT.
Methods:
In response to IFN-α, STAT status, HCV replication, and antiviral gene expression were analyzed in human hepatoma Huh7.5.1 cells before and after cell culture-derived HCV infection.
Results:
IFN-α treatment induced expression and phosphorylation of STAT1 and STAT2 in Huh7.5.1 cells. Pretreatment of Huh7.5.1 cells with a mAb to IFN alpha receptor (IFNAR) 2 decreased IFN-α-dependent phosphorylation of STAT1 and STAT2, whereas pretreatment with an IFNAR1 mAb increased such phosphorylation, suggesting that IFNAR mediates IFN-α-triggered STAT signaling. During HCV infection, STAT1 and STAT2 phosphorylation could be rescued by IFN-α and IFN-α-induced phosphorylation of STAT1 and STAT2 was impaired. Inhibition of STAT pathway by Jak inhibitor I significantly enhanced HCV RNA replication and viral protein expression. Antiviral genes coding for IFN regulatory factor 9 and IFN-stimulated gene 15 were up-regulated by IFN-α during HCV infection but such up-regulation was abrogated by Jak inhibitor I.
Conclusion:
These results establish that activation of STAT pathway is essential for anti-HCV efficacy of IFN-α. Impairment of IFN-α-triggered STAT signaling by HCV may account for evading IFN-α response.
Insights
Interferon-alpha (IFN-α) effectively combats Hepatitis C virus (HCV) by activating the STAT pathway. However, HCV infection impairs this crucial signaling, allowing the virus to evade treatment.
Area of Science:
- Virology
- Immunology
- Molecular Biology
Background:
- Interferon-alpha (IFN-α) is a primary therapy for Hepatitis C virus (HCV) infection.
- The Signal Transducer and Activator of Transcription (STAT) pathway is critical for IFN-α's antiviral activity.
Purpose of the Study:
- To investigate the impact of IFN-α on HCV replication and antiviral gene expression via the STAT pathway.
- To elucidate the role of STAT signaling in the host's response to HCV infection and IFN-α treatment.
Main Methods:
- Analysis of STAT pathway activation, HCV replication, and antiviral gene expression in Huh7.5.1 cells.
- Utilized IFN-α treatment, anti-IFNAR antibodies, and a JAK inhibitor (Jak inhibitor I) to modulate signaling pathways.
- Assessed STAT1 and STAT2 phosphorylation, HCV RNA replication, and expression of antiviral genes like IRF9 and ISG15.
Main Results:
- IFN-α induced STAT1 and STAT2 phosphorylation, mediated by IFNAR1 and IFNAR2.
- HCV infection impaired IFN-α-induced STAT phosphorylation.
- Inhibition of the STAT pathway with Jak inhibitor I significantly increased HCV replication and viral protein levels.
- IFN-α-induced upregulation of antiviral genes (IRF9, ISG15) was blocked by Jak inhibitor I.
Conclusions:
- STAT pathway activation is essential for the anti-HCV effects of IFN-α.
- HCV evades IFN-α therapy by disrupting STAT signaling pathways.
More Related Videos
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents